- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
More ▼
Key statistics
On Tuesday, Organon & Co (OGN:NYQ) closed at 20.98, -12.87% below its 52-week high of 24.08, set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.44 |
---|---|
High | 21.16 |
Low | 20.86 |
Bid | 20.52 |
Offer | 21.01 |
Previous close | 20.98 |
Average volume | 1.64m |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.15 |
Market cap | 5.40bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 5.34% |
Div ex-date | May 10 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 15 minutes, as of May 29 2024 00:00 BST.
More ▼